Linked foreign T-cell help activates self-reactive CTL and inhibits tumor growth

Journal of Immunology

Volumn 175, Issue 1, 2005, Pages 329-334

  Steinaa, Lucilla ^a   Rasmussen, Peter Birk ^a   Wegener, Anne Marie ^a   Sonderbye, Lene ^a   Leach, Dana R ^a   Rygaard, Jørgen ^b   Mouritsen, Søren ^a   Gautam, Anand M ^a,c  

^a Pharmexa AS   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c PRINCESS ALEXANDRA HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; PEPTIDE; SERYLISOLEUCYLISOLEUCYLASPARAGYLPHENYLALANYLGLUTAMINYLLYSYLLEUCINE; TUMOR VACCINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY AFFINITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CELL COMPARTMENTALIZATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; HELPER CELL; IMMUNIZATION; IMMUNOLOGICAL TOLERANCE; IMMUNOREACTIVITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

EID: 21244435520     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.175.1.329     Document Type: Article

References (41)

1. + T-helper and a T-killer cell. Nature 393: 474-478.
2. Bennett, S. R., F. R. Carbone, F. Karamalis, R. A. Flavell, J. F. Miller, and W. R. Heath. 1998. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 393: 478-480.
3. Schoenberger, S. P., R. E. Toes, E. I. van der Voort, R. Offringa, and C. J. Melief. 1998. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393: 480-483.
4. Liu, G. Y., P, J. Fairchild, R. M. Smith, J. R. Prowle, D. Kioussis, and D. C. Wraith. 1995. Low avidity recognition of self-antigen by T cells permits escape from central tolerance. Immunity 3: 407-415.
5. Bouneaud, C., P. Kourilsky, and P. Bousso. 2000. Impact of negative selection on the T cell repertoire reactive to a self-peptide: a large fraction of T cell clones escapes clonal deletion. Immunity 13: 829-840.
6. Sandberg, J. K., L. Franksson, J. Sundback, J. Michaelsson, M. Petersson, A. Achour, R. P. Wallin, N. E. Sherman, T. Bergman, H. Jornvall, et al. 2000. T cell tolerance based on avidity thresholds rather than complete deletion allows maintenance of maximal repertoire diversity. J. Immunol. 165: 25-33.
7. + T cell responses in vivo. J. Immunol. 171: 6339-6343.
8. + T lymphocytes. Nature 421: 852-856.
9. + cells after a transient response to antigen. Eur. J. Immunol. 23: 1963-1967.
10. + T cells. J. Exp. Med. 184: 863-871.
11. Bourgeois, C., H. Veiga-Fernandes, A. M. Joret, B. Rocha, and C. Tanchot. 2002. CD8 lethargy in the absence of CD4 help. Eur. J. Immunol. 32: 2199-2207.
12. + CTL in vivo with peptide vaccine constructs. J. Immunol. 152: 549-555.
13. Grohmann, U., R. Bianchi, E. Ayroldi, M. L. Belladonna, D. Surace, M. C. Fioretti, and P. Puccetti. 1997. A tumor-associated and self-antigen peptide presented by dendritic cells may induce T cell anergy in vivo, but IL-12 can prevent or revert the anergic state. J. Immunol. 158: 3593-3602.
14. Diehl, L., A. T. den Boer, S. P. Schoenberger, E. I. van der Voort, T. N. Schumacher, C. J. Melief, R. Offringa, and R. E. Toes. 1999. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy. Nat. Med. 5: 774-779.
15. + T cell- and IL-2-dependent mechanism. Immunity 11: 483-493.
16. Heinmoller, P., C. Gross, K. Beyser, C. Schmidtgen, G. Maass, M. Pedrocchi, and J. Ruschoff. 2003. HER2 status in non-small cell lung cancer: results from patient screening for enrollment to a phase II study of herceptin. Clin. Cancer Res. 9: 5238-5243.
17. Xiong, H. Q., A. Rosenberg, A. LoBuglio, W. Schmidt, R. A. Wolff, J. Deutsch, M. Needle, and J. L. Abbruzzese. 2004. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II trial. J. Clin. Oncol. 22: 2610-2616.
18. Henry, M. D., S. Wen, M. D. Silva, S. Chandra, M. Milton, and P. J. Worland. 2004. A prostate-specific membrane antigen-targeted monoclonal antibody-chemotherapeutic conjugate designed for the treatment of prostate cancer. Cancer Res. 64: 7995-8001.
19. Kurts, C., W. R. Heath, F. R. Carbone, J. Allison, J. F. Miller, and H. Kosaka. 1996. Constitutive class I-restricted exogenous presentation of self antigens in vivo. J. Exp. Med. 184: 923-930.
20. + T cells. J. Exp. Med. 186: 239-245.
21. Kurts, C., R. M. Sutherland, G. Davey, M. Li, A. M. Lew, E. Blanas, F. R. Carbone, J. F. Miller, and W. R. Heath. 1999. CD8 T cell ignorance or tolerance to islet antigens depends on antigen dose. Proc. Natl. Acad. Sci. USA 96: 12703-12707.
22. Moore, M. W., F. R. Carbone, and M. J. Bevan. 1988. Introduction of soluble protein into the class 1 pathway of antigen processing and presentation. J. Immunol. 54: 777-785.
23. Panina-Bordignon, P. A. Tan, A. Termijtelen, S. Demotz, G. Corradin, and A. Lanzavecchia. 1989. Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells. Eur. J. Immunol. 12: 2237-2242.
24. Maecker, H. T., D. T. Umetsu, R. H. DeKruyff, and S. Levy. 1998. Cytotoxic T cell responses to DNA vaccination: dependence on antigen presentation via class II MHC. J. Immunol. 161: 6532-6536.
25. Duch, M., A. Tolstrup, I. Dalum, T., Jespersen, S. Mouritsen, and F. S. Pedersen. 1999. Functional testing of a bicistronic retroviral vector for intracellular peptide production. BioTechniques 26: 1032-1036.
26. Shimonkevitz, R., S. Colon, J. W. Kappler, J. Boymel, and H. M. Grey. 1984. Antigen recognition by H-2-restricted T cells. II. A tryptic ovalbumin peptide that substitutes for processed antigen. J. Immunol. 133: 2067-2074.
27. Higgins, A. D., M. A. Mihalyo, P. W. McGary, and A. J. Adler. 2002. CD4 cell priming and tolerization are differently programmed by APCs upon initial engagement. J. Immunol. 168: 5573-5581.
28. + T cell help. J. Exp. Med. 186: 65-70.
29. Sprent, J., and H. Kishimoto. 2002. The thymus and negative selection. Immunol. Rev. 185: 126-135.
30. Sprent, J., and C. D. Surh. 2003. Knowing one's self: central tolerance revisited. Nat. Immunol. 4: 303-304.
31. + T cell tolerance to peripherally expressed antigens. J. Immunol. 163: 723-727.
32. Allison, A. C. 1997. Immunological adjuvants and their modes of action. Arch. Immunol. Ther. Exp. (Warsz.). 45: 141-147.
33. Billiau, A., and P. Matthys. 2001. Modes of action of Freund's adjuvants in experimental models of autoimmune diseases. J. Leukoc. Biol. 70: 849-860.
34. Morgan, D. J., H. T. C. Kreuwel, S. Fleck, H. I. Levitsky, D. M. Pardoll, and L. A. Sherman. 1998. Activation of low avidity CTL specific for a self epitope results in tumor rejection but not autoimmunity. J. Immunol. 160: 643-651.
35. Ross, J., K. Gray, D. Schenkein, B. Greene, G. S. Gray, J. Shulok, P. J. Worland, A. Celniker, and M. Rolfe. 2003. Antibody-based therapeutics in oncology. Expert Rev. Anticancer Ther. 3: 107-121.
36. Ross, J. S., D. P. Schenkein, R. Pietrusko, M. Rolfe, G. P. Linette, J. Stec, N. E. Stagliano, G. S. Ginsburg, W. F. Symmans, L. Pusztai, and G. N. Hortobagyi. 2004. Targeted therapies for cancer 2004. Am. J. Clin. Pathol. 122: 598-609.
37. Harris, M. 2004. Monoclonal antibodies as therapeutic agents for cancer. Lancet Oncol. 5: 292-302.
38. Dalum, I., M. R. Jensen, P. Hindersson, H. I. Elsner, and S. Mouritsen. 1996. Breaking of B cell tolerance toward a highly conserved self protein. J. Immunol. 157: 4796-4804.
39. Dalum, I., D. M. Butler, M. R. Jensen, P. Hindersson, L. Steinaa, A. M. Waterston, S. N. Grell, M. Feldmann, H. I. Elsner, and S. Mouritsen. 1999. Therapeutic antibodies elicited by immunization against TNF-alpha. Nature Biotechnol. 17: 666-669.
40. Hertz, M., S. Mahalingam, I. Dalum, S. Klysner, J. Mattes, A. Neisig, S. Mouritsen, P. S. Foster, and A. Gautam. 2001. Active vaccination against IL-5 bypasses immunological tolerance and ameliorates experimental asthma. J. Immunol. 167: 3792-3799.
41. Renard, V., L. Sonderbye, K. Ebbehoj, P. B. Rasmussen, K. Gregorius. T. Gottschalk, S. Mouritsen, A. Gautam, and D. R. Leach. 2003. HER-2 DNA and protein vaccines containing potent Th cell epitopes induce distinct protective and therapeutic anti-tumor responses in HER-2 transgenic mice. J. Immunol. 171: 1588-1595.